Profound Medical financials
$5.72−3.38%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $16.1M | $10.7M | $7.2M | $6.7M | $6.9M | $7.3M | $4.2M |
| Gross profit | $11.4M | $7.0M | $4.3M | $3.0M | $3.0M | $3.5M | $2.4M |
| Gross margin | 70.8% | 65.9% | 59.9% | 45.2% | 43.0% | 47.6% | 57.3% |
| Operating income | -$41.3M | -$33.1M | -$28.7M | -$32.1M | -$30.3M | -$18.9M | -$14.9M |
| Net income | -$42.6M | -$27.8M | -$28.3M | -$28.7M | -$30.7M | -$21.6M | -$15.2M |
| Net margin | −264.4% | −260.4% | −393.4% | −429.1% | −446.7% | −296.0% | −364.7% |
| Diluted EPS | $-1.41 | $-1.12 | $-1.34 | $-1.38 | $-1.50 | $-1.25 | $-1.37 |
| EBITDA | -$40.7M | -$32.1M | -$27.7M | -$28.2M | -$28.7M | -$17.6M | -$13.7M |
| Operating cash flow | -$38.2M | -$23.5M | -$22.6M | -$25.8M | -$22.4M | -$20.6M | -$15.1M |
| Free cash flow | -$38.4M | -$23.5M | -$22.6M | -$25.8M | -$22.4M | -$20.6M | -$15.1M |
| Diluted shares | 30.2M | 24.8M | 21.2M | 20.8M | 20.5M | 17.3M | 11.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $59.7M | $54.9M | $26.2M | $46.5M | $67.2M | $83.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $4.5M | $4.7M | $7.1M | $7.2M | $0.00 | $0.00 |
| Total assets | $77.5M | $70.2M | $44.0M | $64.4M | $86.8M | $104.6M |
| Total liabilities | $11.0M | $9.8M | $12.7M | $12.4M | $6.2M | $7.3M |
| Shareholders' equity | $66.4M | $60.4M | $31.2M | $52.0M | $80.6M | $97.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology